Alzheimer’s disease type 15 (often shortened to AD15) is a rare, inherited form of dementia. Families with this condition develop gradual problems with memory, thinking, language, and daily functioning. Doctors first noticed that the illness in these families looks like Alzheimer’s disease but can also show features that resemble frontotemporal dementia (behavior and language changes). In historical reports, some affected family members had Alzheimer-like symptoms without the usual “neurofibrillary tangles” of tau protein on brain tissue studies, which is why AD15 is also known as “Alzheimer disease without neurofibrillary tangles.” Genetic studies linked the condition to a region on chromosome 3 (3q22–q24), suggesting there is a gene in that area that increases risk in these families. Inheritance has been reported as autosomal dominant, which means one changed copy of the gene from either parent can be enough to cause the condition in an adult child. Because the exact gene has not been fully established for all families and AD15 is very rare, medical information is limited and still evolving. Genetic Rare Disease Center+1
Alzheimer’s disease slowly damages brain cells. People first notice short-term memory trouble, getting lost, repeating questions, or struggling to find words. Over time, managing money, medicines, cooking, and conversation become hard. In AD-15, the day-to-day symptoms feel like “regular” Alzheimer’s, but the brain tissue lacks the usual tau tangles; that suggests a different disease pathway even though amyloid plaques can still be present. Doctors diagnose Alzheimer’s in life with symptoms and biomarkers (spinal fluid, blood tests, or brain scans) and confirm amyloid before starting anti-amyloid medicines. BioMed Central+1
Other names
Doctors and databases may use several labels for the same condition. You may see:
Alzheimer disease 15
Alzheimer’s disease type 15
AD15
Alzheimer disease without neurofibrillary tangles
Alzheimer disease-15; Alzheimer’s disease 15, late onset
All of these refer to the same rare, chromosome-3–linked familial condition. Genetic Rare Disease Center+1
Types
There is no official, fixed “type list” for AD15. However, published descriptions suggest different clinical patterns can appear across or within families. Think of these as presentations rather than strict categories:
Amnestic (memory-first) pattern: short-term memory loss is the main and earliest feature, similar to typical Alzheimer’s disease. Genetic Rare Disease Center
Behavioral/Frontal pattern: early changes in personality, judgment, empathy, or inhibition—overlapping with frontotemporal dementia features. Genetic Rare Disease Center+2Alzheimer’s Association+2
Language-led pattern: word-finding trouble, reduced fluency, or understanding problems come before memory issues. Alzheimer’s Association+1
Visuospatial/Parietal pattern: difficulty judging distances, navigating, or assembling objects; may look like posterior cortical involvement. MalaCards
Mixed pattern: combinations of the above over time; the presentation can change as the disease advances. Genetic Rare Disease Center
These patterns reflect how the disease affects different brain networks in different people. Genetic Rare Disease Center
Causes
Important context: In AD15, the core cause appears to be a heritable change linked to chromosome 3 (3q22–q24) in affected families. Many other items below act as mechanisms or modifiers—they can shape risk, onset age, and symptoms but are not the primary familial mutation. Genetic Rare Disease Center+1
Chromosome-3 (3q22–q24) familial locus: the defining feature of AD15; points to a gene in this region driving disease in these families. MalaCards
Autosomal-dominant inheritance: one altered copy can be enough; risk is ~50% for each child of an affected parent. Genetic Rare Disease Center
Amyloid-beta (Aβ) pathway stress: Alzheimer biology centers on mis-handling of Aβ; abnormal production/clearance can injure synapses. PMC
Tau pathway differences: classic Alzheimer’s shows tau tangles; in AD15, historical reports noted absent tangles in some cases, suggesting alternative pathways or timing. Genetic Rare Disease Center
Endosomal/trafficking dysfunction: mis-sorting of proteins like APP can increase Aβ; human and animal work shows this mechanism matters in AD biology. BioMed Central+1
Lipid and cholesterol handling problems: lipid genes (like APOE) strongly shape Alzheimer risk; lipid biology influences Aβ and inflammation. Practical Neurology
Neuroinflammation: microglial and astrocyte activation can worsen neuronal injury once pathology begins. Journal of Nuclear Medicine
Synaptic dysfunction: early loss of synaptic efficiency drives subtle cognitive change before brain shrinkage is obvious. Journal of Nuclear Medicine
Mitochondrial stress and oxidative injury: energy failure and reactive oxygen species contribute to neuron vulnerability. Journal of Nuclear Medicine
Vascular contributions: small-vessel disease, reduced perfusion, and cardiovascular risks can accelerate decline alongside Alzheimer biology. Nature
Insulin resistance/brain glucose dysregulation: metabolic stress may worsen amyloid and tau pathways and cognition. Journal of Nuclear Medicine
Sleep disruption: poor sleep reduces Aβ clearance and worsens cognitive performance over time. Journal of Nuclear Medicine
Head injury history: prior traumatic brain injury can increase later dementia risk. Wikipedia
Depression and chronic stress: associated with increased risk and faster progression in Alzheimer syndromes. Wikipedia
Hypertension and other midlife vascular risks: uncontrolled risks add cumulative brain injury. Wikipedia
Genetic risk beyond the AD15 locus (e.g., APOE ε4): can modify age at onset and severity in Alzheimer biologic disease. Practical Neurology
Protein processing imbalances beyond Aβ (proteostasis): failure of clearance systems (autophagy/lysosome) may amplify pathology. Journal of Nuclear Medicine
Co-pathologies (e.g., TDP-43, Lewy bodies): mixed proteinopathies are common in dementia and can alter presentation. Journal of Nuclear Medicine
Environmental toxins and exposures: evidence is emerging but still limited; any effect is likely modest compared with genetics. Journal of Nuclear Medicine
Aging: even with a strong genetic driver, normal aging processes lower brain resilience and unmask symptoms. Journal of Nuclear Medicine
Symptoms
Symptoms build slowly. They vary by person and by the clinical pattern. Early signs may be subtle.
Short-term memory loss: repeating questions, misplacing items, missing appointments. Genetic Rare Disease Center
Executive difficulty: planning, organizing, multitasking, and decision-making become harder. Genetic Rare Disease Center
Word-finding trouble: slow speech, “tip-of-the-tongue” moments, or using fewer words. Alzheimer’s Association
Understanding problems: trouble following conversations or complex instructions. Alzheimer’s Association
Behavior or personality change: apathy, impulsivity, lack of empathy, or disinhibition can appear early in some families. Genetic Rare Disease Center+1
Poor judgment and safety awareness: risky choices, financial errors, or vulnerability to scams. Alzheimer’s Association
Visuospatial trouble: getting lost, judging distances poorly, mis-reaching for objects. MalaCards
Attention and concentration problems: easy distractibility and mental fatigue. Genetic Rare Disease Center
Mood symptoms: anxiety, irritability, or depression can accompany cognitive changes. Alzheimer’s Association
Loss of insight: the person may underestimate their difficulties. Alzheimer’s Association
Social withdrawal: fewer hobbies and smaller social engagement. Alzheimer’s Association
Sleep changes: insomnia, fragmented sleep, or daytime sleepiness. Journal of Nuclear Medicine
Apraxia (how-to problems): difficulty carrying out learned tasks like dressing or using tools. Alzheimer’s Association
Gait or motor changes (sometimes): slower steps or mild parkinsonian features in some individuals. Alzheimer’s Association
Progressive daily-life impact: need for help with finances, medications, cooking, and eventually personal care. Genetic Rare Disease Center
Diagnostic tests
Big picture: Modern guidelines encourage a biological definition of Alzheimer’s using biomarkers for Amyloid (A), Tau (T), and Neurodegeneration (N)—called the AT(N) framework. In practice, clinicians combine careful history and exam with cognitive testing, blood/CSF markers, and brain imaging. Note: because AD15 was historically described without neurofibrillary tangles, some individuals might have atypical tau findings (e.g., low tau-PET signal) even with Alzheimer-like symptoms; this remains an area of active study. PMC+3PMC+3Alzheimer’s Journals+3
A) Physical examination (bedside, in the clinic)
General neurologic exam
Doctors check strength, reflexes, eye movements, sensation, coordination, and gait. This helps rule out stroke, Parkinson’s disease, and other conditions that can mimic dementia or add to it. Alzheimer’s AssociationFunctional assessment of daily living
Questions and observation about dressing, cooking, shopping, finances, and medication management show how thinking problems affect real life. Alzheimer’s AssociationBehavioral and mood screening
Brief tools and direct conversation look for apathy, depression, anxiety, disinhibition, and loss of empathy—features that may overlap with frontotemporal dementia. Alzheimer’s AssociationNeurologic gait and balance check
Simple walking tests can reveal frontal network involvement (slowed, cautious gait) or other neurologic disease. Alzheimer’s Association
B) Manual/bedside cognitive tests (paper-and-pencil or brief tablet tests)
Mini-Mental State Examination (MMSE)
A 30-point screening tool for orientation, memory, attention, and language. Lower scores suggest cognitive impairment and track progression. Alzheimer’s AssociationMontreal Cognitive Assessment (MoCA)
More sensitive to early impairment; tests executive function, visuospatial skills, attention, memory, and language. Helpful in mild disease. Alzheimer’s AssociationClock-drawing test
A quick test of planning, visuospatial skill, and attention. Errors can appear early in parietal/visuospatial patterns. Alzheimer’s AssociationSemantic and letter fluency
Naming animals in one minute or words beginning with a letter. Low scores suggest frontal or temporal lobe involvement. Alzheimer’s AssociationBoston Naming Test (or brief naming tasks)
Assesses word-finding and semantic memory; sensitive to language-led presentations. Alzheimer’s AssociationTrail Making (A/B) or similar attention/executive tasks
Measures processing speed and mental flexibility—often affected early in frontal/attention patterns. Alzheimer’s Association
C) Laboratory and pathological/biomarker tests
Basic blood work to exclude mimics
Blood count, electrolytes, liver/kidney panels, TSH (thyroid), vitamin B12/folate, sometimes syphilis/HIV when clinically indicated—these rule out reversible causes that can worsen cognition. BlueShieldCACSF amyloid-β42 or Aβ42/40 ratio (A-biomarker)
Low CSF Aβ42 (or a low Aβ42/40 ratio) indicates brain amyloid deposition. It is one of the “A” markers in the AT(N) framework. PMC+1CSF total tau and phosphorylated tau (p-tau) (T-biomarkers)
Elevated CSF tau and p-tau suggest tau pathology or neuronal injury. In classic Alzheimer’s, p-tau is typically high; in AD15, tau findings may be atypical in some individuals. PMC+1Plasma biomarkers (emerging, clinic-ready in many centers)
Blood tests such as plasma p-tau217/p-tau181 and Aβ42/40 ratio can help detect Alzheimer biology and guide who needs more invasive testing. PMC+1Genetic counseling and testing (family-based)
In families with several affected members across generations or very early onset, clinicians may discuss gene panels for familial Alzheimer genes and research-based testing. For AD15, the key point is the chromosome-3 linkage in reported families; genetic testing is guided by specialists. Genetic Rare Disease Center+1
D) Electrodiagnostic tests
Electroencephalogram (EEG)
Looks for seizure activity or other causes of confusion (for example, delirium). EEG is often normal or shows only mild slowing in degenerative dementias but helps exclude other problems. Journal of Nuclear MedicineEvent-related potentials (e.g., P300, research/adjunctive)
These measure brain responses to stimuli and can reflect slowed cognitive processing; used more in research than in routine clinics. Journal of Nuclear Medicine
E) Imaging tests
MRI brain (with volumetrics when available)
Shows patterns of shrinkage (atrophy). In amnestic presentations, the hippocampus and medial temporal lobes shrink first; frontal or parietal atrophy may appear in other patterns. MRI also rules out stroke, tumor, or normal-pressure hydrocephalus. Journal of Nuclear MedicineFDG-PET (glucose metabolism PET)
Shows regions of reduced brain metabolism. Alzheimer patterns often involve posterior cingulate/precuneus and parietotemporal cortices; frontotemporal patterns show frontal or anterior temporal hypometabolism. PMCAmyloid-PET and Tau-PET
Amyloid-PET detects Aβ plaques (A-positive). Tau-PET detects tau tangles (T-positive) and often correlates best with symptom severity in typical AD. In AD15, amyloid-PET may be positive while tau-PET can be unexpectedly low/negative in some individuals, reflecting the historic “without neurofibrillary tangles” description—an active research area. PMC+3PMC+3ScienceDirect+3
Non-pharmacological treatments (therapies & others)
Each item = Description • Purpose • Mechanism (how it helps)
Cognitive Stimulation Therapy (CST): small-group activities that exercise memory, language, and problem-solving • aims to slow decline and support confidence • repeated, structured practice strengthens remaining networks (“use it to keep it”). Cochrane Library
Regular aerobic exercise: brisk walking, cycling, swimming most days • improves thinking, mood, and function • boosts blood flow, neurotrophic factors, and sleep. PubMed
Resistance / balance training: light weights, tai chi • reduces falls and supports independence • strengthens muscles and balance pathways. PubMed
Treat hearing loss (hearing aids/cochlear consult): • slows cognitive decline in high-risk adults • reduces cognitive load and social isolation. The Lancet+1
Optimize vision (glasses/cataract care): • supports orientation and safety • more sensory input = less confusion. alzint.org
Sleep hygiene & treating sleep apnea: consistent schedule, CPAP when needed • better memory, mood • restores synaptic health and amyloid clearance during deep sleep. PMC
Structured daily routine: calendars, labels, pill boxes • lowers anxiety and errors • external “scaffolding” supports memory.
Environmental simplification & safety: remove trip hazards, stove timers, door alarms • prevents accidents • reduces cognitive load.
Caregiver education & skills training: • reduces crises and hospitalizations • teaches communication, de-escalation, and activity planning.
Occupational therapy (OT): task breakdown and home setup • keeps self-care going longer • matches tasks to ability.
Speech-language therapy: word-finding practice, communication strategies • improves conversation • builds compensations.
Nutrition support & hydration plan: finger foods, oral supplements if weight loss • maintains energy and immunity • prevents delirium from dehydration.
Social engagement / day programs: • lifts mood and motivation • reduces isolation-related decline.
Reminiscence & music therapy: favorite songs/photos • soothes agitation, sparks recall • bypasses damaged circuits via preserved musical and emotional memory.
Bright light exposure/daytime outdoor time: • stabilizes sleep-wake cycles • entrains circadian rhythm. PMC
Mind-body (yoga, tai chi, mindfulness): • reduces stress and anxiety • dampens cortisol/inflammation.
Vascular risk control (with clinicians): BP, diabetes, LDL • slows mixed pathology • protects small vessels. The Lancet
Smoking cessation & alcohol moderation: • protects brain and heart • reduces oxidative stress. The Lancet
Air-quality improvement (HEPA filters, avoid smoke): • lowers exposure to PM2.5 • reduces pollution-related risk. BMJ+1
Advance care planning early: • aligns care with values • reduces crisis decisions later.
Drug treatments
Important: Only start/adjust medicines with your clinician. Anti-amyloid antibodies require confirmed brain amyloid and careful MRI monitoring for ARIA (swelling/bleeding).
Donepezil (cholinesterase inhibitor): 5 mg nightly for 4–6 weeks → 10 mg nightly (some use 23 mg for moderate–severe) • boosts acetylcholine for memory/attention • nausea, diarrhea, vivid dreams, bradycardia. FDA Access Data+1
Rivastigmine patch: 4.6 mg/24 h → 9.5–13.3 mg/24 h daily • same purpose as above; patch lowers GI upset • skin irritation, nausea; remove/replace daily. Novartis+1
Galantamine ER: 8 mg daily → 16–24 mg daily • cholinesterase inhibition + nicotinic modulation • GI upset, weight loss; avoid in severe kidney/liver disease. FDA Access Data+1
Memantine (NMDA antagonist): IR 10 mg twice daily or ER 28 mg daily (titrate weekly) • improves attention/behavior in moderate–severe AD • dizziness, headache, constipation. DailyMed
Lecanemab (Leqembi®): 10 mg/kg IV every 2 weeks for 18 months → continue q2w or maintenance q4w; weekly 360 mg SC now an option after IV initiation • removes amyloid; slows decline in early AD • ARIA risk (MRI monitoring), infusion reactions. FDA Access Data+2media-us.eisai.com+2
Donanemab (Kisunla®): 700 mg IV q4w ×3 then 1400 mg q4w (label now supports a gentler titration to lower ARIA) • removes amyloid; slows early AD • ARIA, headaches; MRI monitoring. U.S. Food and Drug Administration+2FDA Access Data+2
Brexpiprazole for agitation in AD: start low per label • reduces severe agitation • dopamine/serotonin modulation; boxed warning (mortality in elderly with dementia), stroke risk, weight gain, akathisia—use only when benefits outweigh risks. U.S. Food and Drug Administration
Citalopram (10–20 mg/day) for agitation/anxiety/depression • serotonergic calming • QT prolongation, hyponatremia; monitor older adults. (Evidence from CitAD; SSRIs may have mixed long-term cognitive associations.) JAMA Network
Sertraline (25–100 mg/day) for depression/anxiety • SSRI; improves mood • GI upset, hyponatremia, sleep change.
Mirtazapine (7.5–15 mg hs) for poor sleep/appetite • noradrenergic/serotonergic • weight gain, sedation.
Trazodone (25–100 mg hs) for insomnia/agitation • serotonergic; sedating • orthostasis, morning grogginess.
Suvorexant / lemborexant (orexin antagonists) for insomnia • restores sleep architecture • next-day somnolence; avoid with severe hepatic impairment.
Prazosin (1–6 mg hs) for nighttime agitation • central α1-blockade • dizziness, low BP. ClinicalTrials.gov
Dextromethorphan-quinidine for agitation (specialist use) • NMDA/σ-1 + CYP inhibition • falls, dizziness, QT risk. PubMed
Short-term antipsychotics (e.g., risperidone, quetiapine) only for dangerous agitation/psychosis after non-drug steps • dopamine blockade • stroke/mortality risk—lowest dose, shortest time.
Cholinesterase + memantine combo (fixed-dose Namzaric®) when already stable on both • symptom support • combined mechanisms; same side effects as parts. RxAbbVie
Headache, constipation, sleep, depression adjuncts (e.g., stool softeners, melatonin) tailored to symptoms • comfort and stability • symptom-specific mechanisms.
Vascular risk meds (statins, BP meds, diabetes meds) when indicated • protect brain vessels • treat comorbidities that accelerate decline. The Lancet
Vaccinations (influenza, COVID-19, pneumococcal) • prevent delirium and hospitalization • immune protection; indirectly supports cognition.
Pain control (acetaminophen first) • untreated pain worsens agitation • central sensitization relief; avoid high anticholinergic burden.
Dietary molecular supplements
Vitamin B12/folate (correct deficiency): supports myelin and homocysteine control; dose per labs. PMC
Vitamin D (correct deficiency): immune/neuro support; dose per labs.
Vitamin E (α-tocopherol): high-dose slowed function in some trials but has bleeding/all-cause mortality signals at very high doses; discuss risks. PMC
Omega-3 (DHA/EPA): mixed results; may help in early/mild disease; typical 1–2 g/day. The Lancet
Curcumin: anti-inflammatory/antioxidant; low bioavailability; emerging formulations; evidence still limited. Alzheimer’s Society
Magnesium (sleep/leg cramps if low): neuronal excitability; dose per diet/labs.
Melatonin (1–3 mg hs): sleep regulation; may reduce sundowning.
MCT oil/ketone esters: energy alternative for neurons; small studies; watch GI effects. Alzheimer’s Research Association
Saffron extract: small trials vs donepezil suggest benefit; quality control varies.
Resveratrol: mixed human data; antioxidant pathways; watch interactions.
Note: Supplements are not cures. They may interact with medicines and can carry bleeding or liver risks—review with your clinician.
Immunity-booster / regenerative / stem-cell” drugs
There are no proven “immunity boosters” or stem-cell drugs that treat Alzheimer’s in routine care. A few are in trials:
Sargramostim (GM-CSF): small phase II signals and ongoing trials; not approved for AD. Possible immune modulation; side effects include injection reactions and blood count changes. Alzheimer’s Journals+1
Allogeneic mesenchymal stem cells (various routes): phase I/II safety; efficacy unproven; investigate only in trials. Frontiers+1
Exosome-based therapies (MSC-EVs): preclinical/early clinical exploration. Aging and Disease
Immune-targeting “repurposed” strategies (research stage).
GV-971 (oligomannate): not approved in the U.S./EU; China’s earlier approval reportedly not renewed in 2025; mechanism may alter gut-brain inflammation. Fierce Pharma+1
Vaccines/antibody variants (next-gen) are under study. For now, lecanemab and donanemab are the only widely approved disease-modifying options for early symptomatic AD with confirmed amyloid. FDA Access Data+1
Procedures / surgeries
These are not standard treatments for Alzheimer’s; they’re research or used for other conditions that can mimic/worsen dementia.
Deep Brain Stimulation (DBS) — fornix or Nucleus Basalis of Meynert: research to modulate memory circuits; mixed/early results; investigational. PMC+1
Focused ultrasound (FUS) to open the blood-brain barrier: experimental to help antibodies reach targets; trials ongoing; risk includes edema/bleeds—research only. PubMed
Vagus nerve stimulation: very preliminary for cognition/behavior; research only. ScienceDirect
CSF shunt for Normal-Pressure Hydrocephalus (NPH): not for AD, but done when a patient has true NPH (gait, incontinence, enlarged ventricles) causing treatable dementia-like symptoms.
Feeding tube (PEG) discussions: generally do not improve survival or quality of life in advanced dementia; focus stays on comfort feeding by hand unless clear goals say otherwise.
Prevention steps
Control blood pressure, diabetes, LDL with your clinician. 2) Be physically active most days. 3) Treat hearing loss and vision problems. 4) Don’t smoke; keep alcohol low. 5) Prioritize sleep; test for sleep apnea if snoring/daytime sleepiness. 6) Stay socially engaged. 7) Keep your brain busy (learn, play, create). 8) Maintain a balanced Mediterranean/MIND-style diet. 9) Reduce air-pollution exposure (filters, clean cooking, avoid smoke). 10) Keep vaccinations up to date (flu, COVID-19, pneumonia). The Lancet+2The Lancet+2
When to see a doctor
Now: sudden confusion, stroke symptoms, dangerous agitation, wandering, severe headache, new weakness, new hallucinations, or head injury.
Soon (book an appointment): memory loss interfering with work/home life, personality change, repeated medication mistakes, getting lost, significant sleep apnea symptoms, or caregiver burnout.
What to eat and what to avoid
Eat more: vegetables (leafy greens), berries, beans, whole grains, fish, olive oil, nuts/seeds, yogurt, herbs/spices; drink water regularly.
Eat less: processed meats, deep-fried foods, sweets/sugary drinks, refined white bread/rice, trans fats, heavy alcohol, very salty foods. (This mirrors the MIND diet, linked to slower cognitive decline.) PMC
FAQs
1) Is AD-15 different from regular Alzheimer’s?
Yes. It’s linked to chromosome 3 and typically lacks tau tangles, but symptoms overlap. Care follows general Alzheimer’s guidance. Genetic Rare Disease Center
2) Can blood tests help diagnose it?
Yes. Plasma p-tau217 and related panels can triage who needs CSF or PET, with accuracy approaching those tests. JAMA Network+1
3) Do I need a lumbar puncture or PET scan?
Sometimes. Doctors often confirm amyloid before antibody therapy (lecanemab/donanemab). Alzheimer’s Journals
4) Are there disease-modifying drugs?
Yes—for early AD with confirmed amyloid: lecanemab and donanemab. They slow decline but require MRI monitoring for ARIA. FDA Access Data+1
5) Are these drugs safe?
They have serious but monitorable risks (ARIA). Decision-making is individualized. U.S. Food and Drug Administration
6) Do cholinesterase inhibitors still help?
They can improve symptoms like attention and daily function in many people. FDA Access Data
7) Is there a cure?
Not yet. Best results come from early detection, risk control, structured support, and (when eligible) disease-modifying therapy.
8) Do supplements cure it?
No. Some may support sleep, mood, or nutrition. Discuss safety/benefit before use. The Lancet
9) Are stem-cell or “immune booster” treatments real options now?
Only in clinical trials. Not standard care. Nature+1
10) What about GV-971 (oligomannate)?
It’s not approved in the U.S./EU; China reportedly did not renew its approval in 2025. Fierce Pharma
11) Can hearing aids really help?
Yes—treating hearing loss slows cognitive decline in high-risk older adults. The Lancet
12) Does air pollution matter?
Yes—long-term PM2.5 exposure is linked to higher dementia risk; cleaner air helps. BMJ
13) Are antipsychotics safe for agitation?
They carry stroke and mortality risks in dementia; reserve for dangerous situations after non-drug steps.
14) What if symptoms progress fast?
Call your clinician—rule out infections, medication effects, strokes, or seizures.
15) How can families cope?
Ask for caregiver training, community resources, day programs, and respite services early.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 14, 2025.
